title: The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review.
abstract: Insulin resistance is the main pathologic mechanism that links the constellation of clinical, metabolic and anthropometric traits with increased risk for cardiovascular disease and type II diabetes mellitus. These traits include hyperinsulinemia, impaired glucose intolerance, endothelial dysfunction, dyslipidemia, hypertension, and generalized and upper body fat redistribution. This cluster is often referred to as insulin resistance syndrome. The progression of insulin resistance to diabetes mellitus parallels the progression of endothelial dysfunction to atherosclerosis leading to cardiovascular disease and its complications. In fact, insulin resistance assessed by homeostasis model assessment (HOMA) has shown to be independently predictive of cardiovascular disease in several studies and one unit increase in insulin resistance is associated with a 5.4% increase in cardiovascular disease risk. This review article addresses the role of insulin resistance as a main causal factor in the development of metabolic syndrome and endothelial dysfunction, and its relationship with cardiovascular disease. In addition to this, we review the type of lifestyle modification and pharmacotherapy that could possibly ameliorate the effect of insulin resistance and reverse the disturbances in insulin, glucose and lipid metabolism.
authors.affiliation: Reddy Cardiac Wellness, Sugar Land, Texas, USA.
authors.forename: Kota J
authors.initials: KJ
authors.lastname: Reddy
authors.forename: Manmeet
authors.initials: M
authors.lastname: Singh
authors.forename: Joey R
authors.initials: JR
authors.lastname: Bangit
authors.forename: Richard R
authors.initials: RR
authors.lastname: Batsell
mesh_terms: D052242:Adiponectin / Q000378:metabolism; D000818:Animals; D050197:Atherosclerosis / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007249:Inflammation / Q000503:physiopathology; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D020738:Leptin / Q000378:metabolism; D008055:Lipids / Q000097:blood; D024821:Metabolic Syndrome / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D012307:Risk Factors; D040242:Risk Reduction Behavior
chemical_list: D052242:Adiponectin; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D020738:Leptin; D008055:Lipids